Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4638 - Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Clinical Research

Tumour Site

Colon and Rectal Cancer


Heinz-Josef Lenz


Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281


H.J. Lenz1, H. Park2, M.A. Shah3, J.D. Berlin4, D. Bruetman5, J. Chaves6, M. Gordon7, R. Patel8, A. Starodub9, J. Liu10, C. Baker Brachmann11, P. Bhargava12, Z.A. Wainberg13, J. Bendell14

Author affiliations

  • 1 Medical Oncology, University of Southern California Keck School of Medicine, 90033 - Los Angeles/US
  • 2 Oncology, Washington University School of Medicine, 63110 - St. Louis/US
  • 3 Department Of Medicine, Weill Cornell Medicine/ New York Presbyterian Hospital, New York/US
  • 4 Medicine, Vanderbilt Ingram Cancer Center, 37232-6307 - Nashville/US
  • 5 Department Of Medicine, Goshen Center for Cancer Care, Goshen/US
  • 6 Department Of Medicine, Northwest Medical Specialties PLLC, Tacoma/US
  • 7 Medical Oncology, HonorHealth Research Institute, Scottsdale/US
  • 8 Department Of Medicine, Comprehensive Blood and Cancer Center, Bakersfield/US
  • 9 Department Of Medicine, Indiana University Health Goshen Hospital, Goshen/US
  • 10 Department Of Biostatistics, Gilead Sciences, Inc., Foster City/US
  • 11 Department Of Biomarkers, Gilead Sciences, Inc., Foster City/US
  • 12 Department Of Clinical research, Gilead Sciences, Inc., Foster City/US
  • 13 Department Of Medicine, UCLA Medical Center, Los Angeles/US
  • 14 Department Of Medicine, Sarah Cannon Research Institute, 37203 - Nashville/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4638


Matrix metalloproteinase-9 (MMP-9) is highly expressed in metastatic colorectal cancer (mCRC) and other advanced cancers and confers an adverse prognosis. In a preclinical CRC model, inhibition of MMP-9 was associated with reduced tumor growth. Andecaliximab (ADX) is a chimeric antibody directed against MMP-9, engineered to remove T cell epitopes and reduce risk of human anti-mouse antibodies. In this phase I multi-cohort study, we evaluated the combination of ADX with standard chemotherapy in patients with previously untreated mCRC. (Clinicaltrials.gov NCT# 01803282).


The study enrolled 45 eligible patients (19 female) with measurable disease and previously untreated mCRC. The median age was 62 years (range 34-78) and 18% (8/45) of patients had received prior adjuvant chemotherapy. Patients were treated with 800 mg ADX IV every two weeks plus standard doses mFOLFOX6 and bevacizumab. Safety and efficacy were assessed. Primary endpoints were safety and tolerability. Exploratory endpoints were investigator-assessed objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Molecular analysis of archival tumor samples was performed.


As of March 5, 2018, the median duration of ADX treatment was 8.8 months. Median PFS follow up time was 13.5 months. The most common adverse events were fatigue (78%), nausea (71%), diarrhea (56%), peripheral sensory neuropathy (49%), decreased appetite (40%), and neutropenia (40%). 38% of patients reported serious adverse events (SAEs). Acute respiratory failure and sepsis (both 4%) were the most common SAEs. Median PFS was 10 months (90% CI 9.0-12.0 months), median duration of response was 8.1 months (90% CI 6.1, 10.4). Overall response rate was 62% (90% CI 49 – 74%) with 4% complete response rate. The response rate was 50% for mutated BRAF, 67% for mutated RAS, 67% for right-sided disease. The median OS was not reached. Study treatment continues in 7% of patients.


Combination of ADX with mFOLFOX6 and bevacizumab was safe and shows response and PFS similar to historical data with FOLFOX-bevacizumab in first-line treatment of patients with previously untreated mCRC.

Clinical trial identification

NCT 01803282.

Legal entity responsible for the study

Gilead Sciences, Inc.


Gilead Sciences, Inc.

Editorial Acknowledgement


H.J. Lenz: Consulting/Advisory Role: Bristol Myers Squibb, Roche, Merck Serono, Bayer; Travel/Expenses: Bayer, Merck Serono; Honoraria: Bristol Myers Squibb, Roche, Merck Serono, Bayer, and Takeda. M. Shah: Research funding: Lilly/ImClone, Gilead Science, Merck, Sanofi/Regeneron, Boston Biomedical. J. Berlin: Research funding: Genetech/Roche, OncoMed, Novartis, Immunomedics, Abbvie, Gilead Science, Merrimack, Taiho Pharmaceuticals, Five Prime Theraputics, Loxo, Vertex, Bayer, Symphogen, Incyte, Pharmacyclics, Karyopharm Theraputics; Consulting/Advisory Role: Celegene, Symphogen, Genetech/Roche, EMD Serono, Aduro Biotech, Cornerstone Pharmaceuticals, Five Prime Theraputics, Opsona Theraputics, Pierre Fabre, Exelixis, Gritstone Oncology, Erytech Pharma, BeiGene, Karyopharm Theraputics; Travel/Expenses: Genetech/Roche, Celgene, Nestle Health Science, End Serene; Honoraria: Genetech, Nestle Health Science; Other: Symphogen, AstraZeneca. J. Chaves: Stock Ownership: Abbott Laboratories, Johnson & Johnson, Merck; Research Funding: Calithera Biosciences, Celgene, EMD Serono, Halozyme, Immune Design, Novartis, Pfizer. A. Starodub: Consultant/Advisor: Sandoz, Bayer; Speakers’ bureau: Bristol Myers Squibb; Travel/Expenses: Bayer, Bristol Myers Squibb, Sandoz. J. Liu, C. Brachmann, P. Bhargava: Employee and stock ownership: Gilead Science Inc. Z.A. Wainberg: Research funding: Novartis, Plexxikon, Pfizer, Merck; Consulting, Advisory role: Sirtex Medical, Amgen, Array BioPharma, Five Prime Therapeutics, Novartis, Lilly, Merck, Merck KGaA, Bristol-Myers Squibb, Aduro Biotech; Speakers’ bureau: Genentech; Travel expenses: Genentech. J. Bendell: Research funding: Lilly, Genetech/Roche, Incyte, Gilead Science, Bristol-Myers Squibb, Leap Theraputics, AstraZeneca/MedImmune, Boston Biomedical, GlaxoSmithKline, Novartis, Array BioPharma, Taiho Pharmaceutical, Celgene, Oncomed, Daiichi Sankyo, Bayer, Apexigen, Kolltan Pharmaceuticals, SynDevRX, Merck, Macrogenics, Five Prime Theraputics, EMD Serono, TG Theraputics, Boehringer Ingelheim, Forty Seven, Stem CentRx, Onyx, Sanofi, Takeda, Abbott/AbbVie, Eisai, Celldex, Agios, ARMO BioScience, CytomX Theraputics, Nektar, Ipsen, Merrimack, Tarveda Theraputics, Tyrogenex, Oncogenex, Marshall Edwars, Pieris Pharmaceuticals, Mersana, Calithera BioScience, Blueprint Medicines, Gritstone Oncology, Evelo Therapeutics, Forma Therapeutics, Forty Seven, EMD Serono, Merus. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.